|
NPPA fixes retail prices of 70 new drug formulations
|
|
Gireesh Babu, New Delhi
March 02 , 2024
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 70 new drug formulations including antidiabetes, anti-hypertension, antibiotics and pain killers among others, for the companies which have applied for price fixing under Form I of the drug price regulations.
The drug formulations for which retail prices has been fixed against application from individual companies include sitagliptin and metformin hydrochloride extended release tablets from Mankind Pharma as marketer, linagliptin and metformin hydrochloride tablets, vildagliptin and metformin hydrochloride tablets and sitagliptin phosphate and metformin hydrochloride tablets from German Remedies Pharmaceuticals, and dapagliflozin with metformin hydrochloride extended release and glimepiride combination tablets from Eris Lifesciences Ltd, Mankind Pharma, Alkem Laboratories, Torrent Pharmaceuticals, Lupin Ltd, and Medley Pharmaceuticals.
The Authority has also fixed the price of certain formulations of sitagliptin phosphate, metformin hydrochloride and glimepiride tablets from Cipla, Alkem Laboratories, Intas Pharmaceuticals, among others.
Retail price of blood pressure combinations olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets from BlueCross Laboratories Pvt Ltd, telmisartan, amlodipine and hydrochlorothiazide from Mankind Pharma, were also fixed in the recent meeting of the Authority.
The other drugs for which the retail price were fixed include antidepressant drug escitalopram oxalate from Lupin Ltd, paracetamol paediatric oral suspension from Aristo Pharmaceuticals, allergy and common cold drug combination chlorpheniramine maleate, dextromethorphan hydrobromide and phenylephrine hydrochloride syrup and antibiotic combination amoxycillin and potassium clavulanate oral suspension, and heart attack and stroke prevention drug combination clopidogrel and aspirin tablets from German Remedies Pharmaceuticals.
The price of antibiotic meropenem and sulbactam for injection containing anhydrous meropenem 1000 mg with a sterile mixture of meropenem and sodium carbonate (Sodium 90.2 mg) and anhydrous sulbactum 500 mg from German Remedies has been fixed at a retail price of Rs. 1,598.75 per vial.
Prices were also fixed for pain and inflammation relief drug trypsin, bromelain, rutoside trihydrate and diclofenac sodium tablets from Intas Pharmaceuticals, respiratory drug montelukast and acebrophylline sustained release tablets from Apex Laboratories, anti-epilepsy drug levetiracetam extended release tablets from Cipla Ltd, pain and inflammation drug combination trypsin chymotrypsin, paracetamol and aceclofenac tablets from Troikaa Pharmaceuticals Ltd, anti-fibrinolytic drug tranexamic acid tablets from Sun Pharmaceuticals Industries, and antifungal drug itraconazole capsules 130 mg (supra-bioavailable formulation) from Aristo Pharmaceuticals, among others.
The authority deferred price fixation of Softdeal Pharmaceuticals' combination ceftriaxone and sulbactam injection following a company communication, while fixed the retail price of Torrent Pharmaceuticals' anti-diabetic combination dapagliflozin, metformin hydrochloride (extended release) and glimepiride tablets without considering the company's representation for revision of the price to retailer (PTR).
The Authority said that it has received a representation from Torrent Pharma on February 13, 2024 for revision in PTR of some of the items appearing in the draft working sheet, but the same was not considered as the price has been calculated based on Pharmatrac data of June 2023, that is the month ending six months prior to receipt of application in January, 2024, and the revised PTR of the line items as claimed by the company is reflected from July, 2023 in Pharmatrac. It also rejected the PTR derived by the company in its representation, pointing that there is no provision to consider it.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|